PL402710A1 - Kompozycje farmaceutyczne zawierajace imatinib lub jego farmaceutycznie dopuszczalna sól oraz sposoby ich otrzymywania - Google Patents

Kompozycje farmaceutyczne zawierajace imatinib lub jego farmaceutycznie dopuszczalna sól oraz sposoby ich otrzymywania

Info

Publication number
PL402710A1
PL402710A1 PL402710A PL40271011A PL402710A1 PL 402710 A1 PL402710 A1 PL 402710A1 PL 402710 A PL402710 A PL 402710A PL 40271011 A PL40271011 A PL 40271011A PL 402710 A1 PL402710 A1 PL 402710A1
Authority
PL
Poland
Prior art keywords
methods
pharmaceutically acceptable
acceptable salt
pharmaceutical compositions
imatinib
Prior art date
Application number
PL402710A
Other languages
English (en)
Other versions
PL234542B1 (pl
Inventor
Sayisiva Prasad Ravula
Anand Kumar Mamidi
Original Assignee
Zaklady Farmaceutyczne Polpharma Spólka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zaklady Farmaceutyczne Polpharma Spólka Akcyjna filed Critical Zaklady Farmaceutyczne Polpharma Spólka Akcyjna
Publication of PL402710A1 publication Critical patent/PL402710A1/pl
Publication of PL234542B1 publication Critical patent/PL234542B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku są kompozycje farmaceutyczne zawierające imatinib lub jego farmaceutycznie dopuszczalną sól oraz sposoby ich otrzymywania.
PL402710A 2010-06-21 2011-06-17 Sposób otrzymywania kompozycji farmaceutycznej zawierającej imatinib lub jego farmaceutycznie dopuszczalną sól PL234542B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1732CH2010 2010-06-21
EP10460039 2010-09-20
PCT/EP2011/003020 WO2011160798A1 (en) 2010-06-21 2011-06-17 Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof

Publications (2)

Publication Number Publication Date
PL402710A1 true PL402710A1 (pl) 2013-09-30
PL234542B1 PL234542B1 (pl) 2020-03-31

Family

ID=44358103

Family Applications (1)

Application Number Title Priority Date Filing Date
PL402710A PL234542B1 (pl) 2010-06-21 2011-06-17 Sposób otrzymywania kompozycji farmaceutycznej zawierającej imatinib lub jego farmaceutycznie dopuszczalną sól

Country Status (4)

Country Link
EP (1) EP2582362A1 (pl)
EA (1) EA029416B1 (pl)
PL (1) PL234542B1 (pl)
WO (1) WO2011160798A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9750700B2 (en) * 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
EP2749271A1 (en) * 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Optimized manufacturing method and pharmaceutical formulation of imatinib
GB201304699D0 (en) * 2013-03-15 2013-05-01 Remedica Ltd Pharmaceutical compositions
EP2803353B1 (en) 2013-05-14 2018-05-23 Hetero Research Foundation Compositions of Imatinib
CN104414988B (zh) * 2013-08-28 2018-07-06 山东新时代药业有限公司 一种达沙替尼片剂及其制备工艺
EA035891B1 (ru) * 2016-01-25 2020-08-27 КРКА, д.д., НОВО МЕСТО Быстродиспергируемая фармацевтическая композиция, включающая ингибитор тирозинкиназы
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
CN107648237B (zh) * 2016-07-26 2022-03-04 江苏豪森药业集团有限公司 氨基嘧啶类化合物的药物组合物及其制备方法
WO2019016673A2 (en) * 2017-07-20 2019-01-24 Kashiv Pharma Llc STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
EP3999063A1 (en) * 2019-07-15 2022-05-25 Novartis AG Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (pl) * 1992-04-03 1994-06-21 Ciba Geigy Ag
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
DE502006005084D1 (de) 2005-08-15 2009-11-26 Siegfried Generics Int Ag Filmtablette oder Granulat enthaltend ein Pyridylpyrimidin
KR101041203B1 (ko) * 2007-09-25 2011-06-13 테바 파마슈티컬 인더스트리즈 리미티드 안정한 이매티닙 조성물

Also Published As

Publication number Publication date
EA029416B1 (ru) 2018-03-30
EA201300034A1 (ru) 2013-05-30
EP2582362A1 (en) 2013-04-24
WO2011160798A1 (en) 2011-12-29
PL234542B1 (pl) 2020-03-31

Similar Documents

Publication Publication Date Title
PL402710A1 (pl) Kompozycje farmaceutyczne zawierajace imatinib lub jego farmaceutycznie dopuszczalna sól oraz sposoby ich otrzymywania
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
DK3284467T3 (da) Nikotinholdige farmaceutiske sammensætninger
IN2014MN02598A (pl)
IN2014DN10670A (pl)
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
EP2609064A4 (en) PHARMACEUTICAL COMPOSITIONS WITH POH DERIVATIVES
DK2673262T3 (da) Fremgangsmåder til fremstilling af quinolinforbindelser og farmaceutiske sammensætninger indeholdende sådanne forbindelser
ZA201206254B (en) Novel salts for the manufacture of pharmaceutical compositions
MX2013001677A (es) Formulaciones estables de linaclotida.
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
TN2012000392A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
MX2014004196A (es) Citramida de rasagilina.
IL231383A0 (en) History of imidazole amines, their preparation and pharmaceutical preparations containing them
MX2015012416A (es) Compuestos heterociclicos y sus usos.
MX2014013664A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
EP2536285A4 (en) SUBSTITUTED CONDENSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOUNDS AND USER METHOD THEREFOR
IT1403282B1 (it) Procedimento per la preparazione di linagliptin
IT1402029B1 (it) Procedimento per la preparazione di erlotinib
ITBS20100012A1 (it) Procedimento per la preparazione di fluazinam
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
DK2588097T3 (da) Farmaceutiske sammensætninger omfattende paracetamol og fremgangsmåde til fremstilling af samme
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
HUE054955T2 (hu) 3-Formilrifamicin S 3-(4-cinnamil-L-piperazinil)-amino származékait tartalmazó gyógyszerészeti készítmények